Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 2349 questions Show Answers
To ask the Scottish Government what steps it is taking to fill any gap in funding for the New Medicines Fund caused by the reduced rebate from the Pharmaceutical Price Regulation Scheme.
To ask the Scottish Government, further to the answer to question S5W-03871 by Shona Robison on 14 November 2016, how much of their allocation each NHS board provided in each year to fund new medicines.
To ask the Scottish Government, further to the answer to question S5W-03871 by Shona Robison on 14 November 2016, how much each NHS board (a) was allocated in 2016-17 and (b) is being allocated in 2017-18.
To ask the Scottish Government when the development of the Scottish Primary Care Information Resource (a) began and (b) will conclude.
To ask the Scottish Government what plans it has to reduce the incidence of lung disease in areas of social deprivation.
To ask the Scottish Government what progress it has made on delivering recommendation 27 of the review by Dr Brian Montgomery on the establishment of a multi-agency task force or equivalent to facilitate discussions on the opportunities afforded by anticipated development in the way that new medicines will be introduced in the future.
To ask the Scottish Government when the multi-agency task force or equivalent group, as recommended by Dr Brian Montgomery, will be established to explore innovative options for managed entry of new medicines.
To ask the Scottish Government what it is doing to ensure that employers provide sufficient accommodations for people with "invisible conditions".
To ask the Scottish Government, in the light of the recommendation in the review by Dr Brian Montgomery that managed access schemes should be developed as an additional option rather than a replacement for patient access schemes, what the principles are for development of new processes; what types of schemes are being considered and what level of flexibility is being built-in to improve access and affordability of innovative new medicines.
To ask the Scottish Government what its approach is to supporting work toward finding new treatments and a cure for cystic fibrosis.